comparemela.com

Latest Breaking News On - Daniella parra - Page 8 : comparemela.com

Comera Life Sciences Announces $4 1 Million Private Placement

By Daniella Parra Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said it completed a $4.1 million private placement of shares and warrants to existing stockholders. The company said it aims to develop new biologic medicines to improve patient access and convenience. Comera has entered into a registration rights agreement to register the resale of the […]

First Watch Serves Up Sizzling Second Quarter Performance

By Daniella Parra First Watch Restaurant Group, Inc. (NASDAQ: FWRG) said revenue increased 17.3% to $216.3 million in the second quarter. The chain opened nine new system-wide restaurants, including six company-owned locations in the quarter, it said in a statement. System-wide sales increased 17.4% to $271.5 million in the quarter, while net income increased […]

Vaxxinity Appoints Dr Peter Powchik as Global Scientific Director

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it appointed Peter Powchik, M.D. as Executive Vice President, Global Scientific Director overseeing its scientific direction and lead development efforts. Powchik was previously Senior Vice President at Regeneron Pharmaceuticals, the company said. Additionally, Ulo Palm, M.D., will transition from Chief Medical Officer to senior advisor, it said. […]

Octave Bioscience Raises $30M for Neurodegenerative Diseases

By Daniella Parra Octave Bioscience said it secured a $30 million extension to its Series B funding round. The investment, led by Novartis, Hikma Ventures and Intermountain Ventures, will accelerate commercialization of their precision care solution for multiple sclerosis (MS) and other neurodegenerative diseases, the company said in a statement. “The strength and breadth of […]

Promontory Therapeutics Expands Clinical Trial for Prostate Cancer Treatment

By Daniella Parra Promontory Therapeutics, a clinical stage pharmaceutical company focused on oncology, said it treated its first four patients in France for late-stage metastatic castration-resistant prostate cancer (mCRPC). The study is being led by oncologist Dr. Karim Fizazi at Gustave Roussy and the Military Hospital (HIA) Bégin in Paris, the company said. The trial […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.